ERBB2 and glioblastoma: Although CAR T cell therapy didn’t improve OS significantly, one glioblastoma patient survived 59 months after EGFRvIII-CAR T cell therapy without post-CAR treatment, and some on HER2-CAR T cell therapy had stable disease up to 29 months.